Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (September 2025)
21 slides from Microbot Medical's investor presentation, Sep 9, 2025
Slide 1: Redefining Endovascular Robotics
Redefining Endovascular Robotics micr DS ical
Slide 2: Safe Harbor Statement
Safe Harbor Statement microbot This document (together with any oral statements made in connection with this document) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, r
Slide 3: Pivotal Company Development
Pivotal Company Development micrese! FDA granted 510(k) clearance for the LIBERTY® BREAKING NEWS Endovascular Robotic System i LIBERTY® is the first single-use, remotely operated robotic system for peripheral endovascular procedures The FDA clearance allows the Company to commence commercialization
Slide 4: Microbot Medical At-a-Glance
Microbot Medical At-a-Glance ibemty Cay Large and Significant €)ae Differentiated First Mover WS: Emergent Market Unmet Needs Robotic Solution Advantage + Many endovascular procedures are + Difficulty navigating complex LIBERTY? is the world’s first fully + LIBERTY?® is the only single-use, life and
Slide 5: Large and Emergent Market
@ Large and Emergent Market ¢ >6 million annual endovascular procedures performed in the US (15 million worldwide) ¢ >$40B spent annually in the US Performed by 15,000 physicians * 9,000 interventional cardiologists * 3,000 interventional radiologists‘ * 3,000 vascular surgeons Performed at 8,000 fa
Slide 6: Initial Target Market: Peripheral Vascular
@ Initial Target Market: Peripheral Vascular microbot INITIAL TARGET ANNUAL i TARGET PROCEDURES (USA): : SPENDING (USA): i PHYSICIANS (USA): 2.3M $15B _ 6,000 Peripheral Vascular , Procedures AVG. ANNUAL # OF : FACILITIES PERFORMING PROCEDURES PER g PROCEDURES (USA): PHYSICIAN (USA): : 2,200 Hospita
Slide 7: Significant Unmet Needs
medical GK Significant Unmet Needs Endovascular procedures are ripe for disruptive innovation that can improve procedure efficiency, HCP health & safety, while enabling access to quality care for both providers and patients 1. Andreassi MG, Piccaluga E, Guagliumi G, et al 2. Andrew S, Abdelmonem M R
Slide 8: Robotic manipulation of guidewires and catheters was successful in all cases
microbot medical Robotic manipulation of guidewires and cathet ith LIBERTY® was successful in all cases, minimizing radiation exposure and maintaining a desirable safety profile’ Participating Physicians Reported LIBERTY Performed as Planned with 92% Relative Reduction in Radiation Exposure 100% Sat
Slide 9: The LIBERTY Endovascular Robotic System is disruptive technology
microbot medical The LIBERTY® Endovascular Robotic System is disruptive technology designed to change the standard of care for endovascular procedures Single-use, fully-disposable without need for capital investment Empowers physicians to precisely steer guidewires and catheters using a handheld rem
Slide 10: First Mover Advantage
it First Mover Advantage LIBERTY® was designed to eliminate barriers and enable adoption of robotics in endovascular procedures Barriers to Adoption Cost of acquisition v Large capital investment v Disposable procedure kit v Annual service agreement micr v Single-use (disposable) device with no init
Slide 11: First Mover Advantage
jt First Mover Advantage icrobot LIBERTY® is the only U.S. commercially available, single-use, robotic system for peripheral endovascular procedures Several companies are developing robotic solutions due to the attractive market and untapped potential Microbot is uniquely positioned for success with
Slide 12: Attractive Reimbursement
Ce) ©) Attractive Reimbursement Targeted procedures have an attractive outpatient reimbursement with capacity to incorporate new technologies including LIBERTY® micr ot medical imbursemeni Y90 for Part 1 — Mapping procedure Dx Angiogram (75726) $43,990.21 Liver Cancer Part 2 — Embolization procedure
Slide 13: Unique Business Model
ea Unique Business Model The fully disposable feature of LIBERTY® offers an attractive business model to position LIBERTY® for commercial success by reducing barriers for entry and increase operational efficiencies for all stakeholders medical No Capital Investment No special Capital Expense (CAPEX)
Slide 14: Commercialization Timeline
Commercialization Timeline microbot Successful execution of regulatory, commercial and launch readiness strategies whe ea ° ach 2 SP —— q=ml =~ AVR PA — : cas ol FDA, BBD, A Commercial Manufacturing & FDA Marketing Sales Team Commence Marketing LIBERTY® Limited — Full LIBERTY® Leadership team Invent
Slide 15: Go-to-Market Strategy
Go-to-Market Strategy microbot Company positioned to accelerate market adoption of the LIBERTY® system * Dedicated direct sales team in the U.S., supplement with distribution channels as needed ¢ Increase manufacturing and build inventory levels to meet anticipated demand ¢ Limited Market Release (L
Slide 16: Focused Growth Initiatives
Focused Growth Initiatives microbot In parallel with U.S. commercialization activities, Company remains focused on generating positive momentum with milestone achievements Expand U.S. and global sales footprint Strategically target markets that accept FDA cleared devices approval process to expedite
Slide 17: Global Intellectual Property Portfolio
Global Intellectual Property Portfolio micrese! LIBERTY® is protected by a strong and growing intellectual property portfolio. 13 , 56 patents issued worldwide patents pending
Slide 18: Experienced Management Team
cut? Experienced Management Team Harel Gadot CEO, President & Chairman LinkedIn PN Earl Adamy Vice President of Strategic Marketing & Business Dev LinkedIn Simon Sharon Chief Technology Officer LinkedIn yn Eran Cohen Vice President of Global Integration LinkedIn a Juan Diaz-Cartelle, MD Chief Medica
Slide 19: Proven Commercial Leadership Team
tr , icrobot (fu? Proven Commercial Leadership Team mer ai Christina Bailey Allison Rosefort Elaina Romano Michael Lytle Lisa Dobbins Vice President of Sales Vice President of Marketing Director of U.S. Operations Manager, Sales Operations Director, Human Resources Linkedin Linkedin LinkedIn & Analy
Slide 20: LIBERTY is a differentiated solution in a large and emergent market
microbot medical LIBERTY® is a differentiated solution in a large and emergent market, with clear unmet needs and attractive reimbursement Granted 510(k) clearance by U.S. FDA in September 2025 for the LIBERTY® Endovascular Robotic System, the first single-use, remotely operated robotic system for e
Slide 21: microbot
microbot medical ir@microbotmedical.com NASDAQ CM: MBOT iberey
Microbot Medical — Investor Presentation (September 2025) on 6ix